{"id":50167,"date":"2025-12-08T21:06:31","date_gmt":"2025-12-08T13:06:31","guid":{"rendered":"https:\/\/flcube.com\/?p=50167"},"modified":"2025-12-08T21:06:32","modified_gmt":"2025-12-08T13:06:32","slug":"anke-biotech-pa3-17-car-t-pediatric-indication-nmpa-accepted","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50167","title":{"rendered":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted"},"content":{"rendered":"\n<p><strong>Anhui Anke Biotechnology (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300009:SHE\">SHE: 300009<\/a>) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed <strong>PA3-17 injection<\/strong> for pediatric and adolescent patients with <strong>relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>PA3-17 injection (CD7-targeted CAR-T cell therapy)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>PersonGen Biotherapeutics (Anke Biotech holds a stake)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Clinical trial application for new pediatric indication<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Pediatric and adolescent R\/R T-ALL\/LBL<\/td><\/tr><tr><td><strong>Current Status<\/strong><\/td><td>Pivotal Phase 2 trial ongoing for adult R\/R T-ALL\/LBL<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (CDE, Aug\u202f2025)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td><strong>First-in-class autologous CD7 CAR-T cell therapy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-mechanism-of-action\">Technology &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>PA3-17<\/strong> is a <strong>CD7-targeted autologous CAR-T cell therapy<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: CD7 antigen expressed on T-cell malignancies<\/li>\n\n\n\n<li><strong>Approach<\/strong>: Engineered patient T-cells to recognize and eliminate CD7-positive tumor cells<\/li>\n\n\n\n<li><strong>First-in-Class<\/strong>: First CD7 CAR-T therapy to receive Breakthrough Therapy Designation in China<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Autologous process requiring patient-specific cell collection and engineering<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-strategic-expansion\">Development Timeline &amp; Strategic Expansion<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>Breakthrough Therapy Designation<\/strong><\/td><td>Aug\u202f2025<\/td><td>Adult R\/R T-ALL\/LBL<\/td><\/tr><tr><td><strong>Adult Phase 2 Trial<\/strong><\/td><td>Ongoing<\/td><td>R\/R T-ALL\/LBL pivotal study<\/td><\/tr><tr><td><strong>Pediatric Application Acceptance<\/strong><\/td><td>08\u202fDec\u202f2025<\/td><td>Expands to patients aged &lt;18 years<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>2026<\/td><td>Double addressable patient population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Patient Population Expansion:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Adults<\/strong>: ~1,500 new R\/R T-ALL\/LBL cases annually in China<\/li>\n\n\n\n<li><strong>Pediatric\/Adolescent<\/strong>: Additional ~800 cases annually<\/li>\n\n\n\n<li><strong>Total Addressable Market<\/strong>: ~2,300 patients\/year with potential CAR-T eligibility<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitive Asset<\/th><th>Company<\/th><th>Target<\/th><th>Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>PA3-17<\/strong><\/td><td>Anke Biotech\/PersonGen<\/td><td>CD7<\/td><td>Phase\u202f2 (adult), IND (pediatric)<\/td><td><strong>First CD7 CAR-T<\/strong><\/td><\/tr><tr><td><strong>GC012F<\/strong><\/td><td>Gracell Bio<\/td><td>CD19\/BCMA<\/td><td>Phase\u202f1\/2 (various)<\/td><td>Dual-target, but not CD7<\/td><\/tr><tr><td><strong>C-CAR039<\/strong><\/td><td>JW Therapeutics<\/td><td>CD19<\/td><td>Approved (DLBCL)<\/td><td>Not for T-ALL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Market Opportunity:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T-ALL\/LBL Treatment Gap<\/strong>: Limited options after relapse; 5-year survival &lt;20% for R\/R patients<\/li>\n\n\n\n<li><strong>CAR\u2011T Efficacy<\/strong>: Early data shows <strong>>80% CR rate<\/strong> in heavily pre-treated adults<\/li>\n\n\n\n<li><strong>Pediatric Unmet Need<\/strong>: No approved CAR-T therapies for pediatric T-cell malignancies globally<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Analysts project <strong>\u00a51.5-2.0 billion<\/strong> peak sales (\u2248\u202fUS$210-280\u202fmillion) if approved across both indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-next-steps\">Strategic Outlook &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Path<\/strong>: Pediatric trial design will mirror adult protocol with age-adjusted dosing<\/li>\n\n\n\n<li><strong>Regulatory Timeline<\/strong>: NMPA review expected to take 6-9 months; Phase\u202f1 pediatric initiation Q3\u202f2026<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Leverages PersonGen&#8217;s established autologous CAR-T production facility<\/li>\n\n\n\n<li><strong>Global Ambition<\/strong>: Data may support future FDA Rare Pediatric Disease designation application<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding PA3-17 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/\u5b89\u79d1\u751f\u7269\uff1a\u5173\u4e8e\u53c2\u80a1\u516c\u53f8PA3-17\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u7533\u62a5\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u5b89\u79d1\u751f\u7269\uff1a\u5173\u4e8e\u53c2\u80a1\u516c\u53f8PA3-17\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u7533\u62a5\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-0e9fa6c5-1b9f-4f95-bf5e-812467c045fa\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/\u5b89\u79d1\u751f\u7269\uff1a\u5173\u4e8e\u53c2\u80a1\u516c\u53f8PA3-17\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u7533\u62a5\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u5b89\u79d1\u751f\u7269\uff1a\u5173\u4e8e\u53c2\u80a1\u516c\u53f8PA3-17\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u7533\u62a5\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/\u5b89\u79d1\u751f\u7269\uff1a\u5173\u4e8e\u53c2\u80a1\u516c\u53f8PA3-17\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u7533\u62a5\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0e9fa6c5-1b9f-4f95-bf5e-812467c045fa\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50169,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[482,21,90,997],"class_list":["post-50167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-anke-biotechnology","tag-car-t","tag-clinical-trial-filings","tag-she-300009"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed PA3-17 injection for pediatric and adolescent patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50167\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted\" \/>\n<meta property=\"og:description\" content=\"Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed PA3-17 injection for pediatric and adolescent patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50167\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:06:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T13:06:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted\",\"datePublished\":\"2025-12-08T13:06:31+00:00\",\"dateModified\":\"2025-12-08T13:06:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167\"},\"wordCount\":448,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0805.webp\",\"keywords\":[\"Anke Biotechnology\",\"CAR-T\",\"Clinical trial filings\",\"SHE: 300009\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50167#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50167\",\"name\":\"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0805.webp\",\"datePublished\":\"2025-12-08T13:06:31+00:00\",\"dateModified\":\"2025-12-08T13:06:32+00:00\",\"description\":\"Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed PA3-17 injection for pediatric and adolescent patients with relapsed\\\/refractory T-cell acute lymphoblastic leukemia\\\/lymphoblastic lymphoma (R\\\/R T-ALL\\\/LBL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50167\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0805.webp\",\"width\":1080,\"height\":608,\"caption\":\"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50167#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted - Insight, China&#039;s Pharmaceutical Industry","description":"Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed PA3-17 injection for pediatric and adolescent patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50167","og_locale":"en_US","og_type":"article","og_title":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted","og_description":"Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed PA3-17 injection for pediatric and adolescent patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL).","og_url":"https:\/\/flcube.com\/?p=50167","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T13:06:31+00:00","article_modified_time":"2025-12-08T13:06:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50167#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50167"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted","datePublished":"2025-12-08T13:06:31+00:00","dateModified":"2025-12-08T13:06:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50167"},"wordCount":448,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50167#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp","keywords":["Anke Biotechnology","CAR-T","Clinical trial filings","SHE: 300009"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50167#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50167","url":"https:\/\/flcube.com\/?p=50167","name":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50167#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50167#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp","datePublished":"2025-12-08T13:06:31+00:00","dateModified":"2025-12-08T13:06:32+00:00","description":"Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products Administration (NMPA) has accepted the clinical trial application for an additional indication of its self-developed PA3-17 injection for pediatric and adolescent patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50167#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50167"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50167#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp","width":1080,"height":608,"caption":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50167#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50167"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50167\/revisions"}],"predecessor-version":[{"id":50171,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50167\/revisions\/50171"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50169"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}